Report error Found 260 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [1-770,'NPG',771-1210]'
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataKd: <0.5nMAssay Description:In some assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and inf...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 1.10nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 2nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 2.30nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 2.46nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 2.72nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 2.82nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 3nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 3.52nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 4.12nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 4.44nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 4.54nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 6.55nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 7.20nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 10nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 12nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 13nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
BLOSSOMHILL THERAPEUTICS, INC.
US Patent
Affinity DataIC50: 20nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
















































